I-Mab Biopharma August 2024 Investor Presentation

I-Mab Biopharma presented its pipeline strategy and clinical development progress in August 2024, focusing on three key oncology assets: uliledlimab (CD73 mAb for mNSCLC), givastomig (CLDN18.2 bispecific for gastric cancers), and ragistomig. The presentation outlines market opportunities and anticipated clinical milestones for the company's immunotherapy portfolio.